DCGI Approves Bharat Biotech's Intranasal COVID-19 Vaccine For Phase III Trials

The Drugs Controller General of India on January 28, approved clinical trials of Intranasal vaccine against COVID-19. Manufactured by Bharat Biotech, the phase III trials will be conducted on 5,000 subjects, who are vaccinated with Covishield or Covaxin, in nine Indian states. If successful after evaluation, the Intranasal vaccine will also be used as booster dose, especially when the nation is fighting COVID-19's new variant Omicron and the third wave.